Bcm-95 Curcumin — Why Bioavailability Is Everything
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
CoQ10 is a molecule your body makes that sits inside your cells’ power stations, called mitochondria. It helps generate energy and neutralizes harmful free radicals produced during that process. Your brain burns through enormous amounts of energy but CoQ10 levels drop as you age. Animal research consistently shows CoQ10 protects against brain degeneration in conditions like Parkinson’s and Alzheimer’s disease, and the science behind why it should work is solid.
The problem is that human clinical trials have largely disappointed. The leading explanation is that CoQ10, taken by mouth, may struggle to cross the blood-brain barrier, a protective filter that separates your bloodstream from your brain tissue. We simply don’t know yet whether oral supplements reach brain cells in meaningful amounts. The timing and form of CoQ10 also matter greatly for absorption.
For someone in midlife wanting to support brain health before any problems appear, the risk-benefit math looks reasonable: CoQ10 is safe, inexpensive, and genuinely important to how mitochondria work. Choosing a highly absorbable form and combining it with other mitochondrial-supporting nutrients makes more sense than taking CoQ10 alone. But it’s not a proven cure for established disease.
Verdict: CoQ10 shows genuine promise for brain health based on sound science, but the gap between animal research and human benefit remains unresolved, making it most valuable as prevention rather than treatment.
What if one of the most important molecules for protecting your brain was something your own body already makes, but quietly stops making enough of as you age? That’s the story of Coenzyme Q10, and it’s more compelling, and more complicated, than most people realise.
Most of us, if we’ve heard of CoQ10 at all, associate it with heart health or energy. But researchers have spent the last four decades investigating something far more significant: whether this remarkable molecule sits at the very centre of how and why our brains age, and whether supplementing it could help slow neurodegeneration in conditions like Alzheimer’s, Parkinson’s, and beyond. Vitacuity has reviewed over 1.77 million research papers and selected the most relevant findings on this topic. What we found is genuinely fascinating, and genuinely honest about where the science still has gaps.
Let’s start at the beginning.
To understand why CoQ10 matters for neurological health, you need to understand what it actually does, and where it lives in your body.
CoQ10, also known as ubiquinone (the name comes from “ubiquitous”, it’s found everywhere in the body), is a fat-soluble compound produced in the inner membranes of your mitochondria [6]. Think of mitochondria as your cells’ power stations. They take the food you eat and convert it into ATP, the actual energy currency your cells run on. Your brain, despite representing only about 2% of your body weight, consumes roughly 20% of your body’s energy. That makes mitochondrial health absolutely central to brain function.
Here’s where CoQ10 comes in. Inside the mitochondria, energy production happens via something called the electron transport chain, a series of protein complexes that pass electrons along like a relay race, ultimately generating ATP [9]. CoQ10 is the essential carrier molecule in this relay. Without it, the chain breaks down, energy production falls, and cells begin to malfunction and die [5].
But CoQ10 does something else equally important. When electrons “leak” from the transport chain, which happens constantly, and increases with age and disease, they react with oxygen to create reactive oxygen species (ROS), also called free radicals. These are destructive molecules that damage cell membranes, proteins, and DNA. CoQ10, in its reduced form (called ubiquinol), is the body’s only fat-soluble antioxidant made internally [9]. It neutralises these free radicals directly, and it also helps recycle other antioxidants like vitamins C and E [1].
So CoQ10 is doing two critical jobs simultaneously: helping generate energy, and mopping up the damage that energy generation inevitably causes. In neurons, cells that are extraordinarily energy-hungry and that you cannot easily replace, this dual role becomes especially important.
The problem? CoQ10 levels in the brain decline with age, and appear to be measurably lower in people with neurodegenerative diseases [6][10]. This has driven decades of research into whether supplementing CoQ10 could protect the brain, or even slow the progression of conditions like Parkinson’s and Alzheimer’s.
One of the most striking recent developments in neurodegenerative research is the recognition that mitochondrial dysfunction and neuroinflammation don’t just coexist, they actively drive each other in a destructive cycle [5].
Here’s how it works. When the electron transport chain malfunctions, whether due to aging, CoQ10 depletion, or disease, it generates excess free radicals. These damage mitochondrial DNA and the membranes around the mitochondria themselves. Fragments of damaged mitochondria then leak into the cell interior, where the immune system recognises them as danger signals (called mitochondrial damage-associated molecular patterns, or mtDAMPs) [5].
This triggers the activation of inflammatory pathways, including the NLRP3 inflammasome, a molecular alarm system associated with chronic brain inflammation. The resulting neuroinflammation then causes further mitochondrial damage, which generates more free radicals, which triggers more inflammation. Round and round it goes.
A 2026 review published in *Biomedicines* mapped this mechanism across Parkinson’s disease, Alzheimer’s disease, ALS, and Huntington’s disease models, identifying the CoQ10 junction in Complex I of the electron transport chain as a critical point of vulnerability [5]. When CoQ10 availability is reduced at this junction, electron leakage increases, the free radical cascade intensifies, and the inflammatory loop is harder to break.
This is not just theoretical. CoQ10 deficiency has been directly measured in brain tissue and cerebrospinal fluid in patients with Parkinson’s disease and Alzheimer’s disease [6][7]. The question, and this is where the research gets genuinely complicated, is whether supplementing CoQ10 orally can actually get it to where it’s needed most.
Evidence grade: Early stage to Promising. The mechanistic picture is compelling and increasingly well-characterised. Human clinical trials, however, have not yet matched the promise of the lab.
Parkinson’s disease is characterised by the progressive death of dopaminergic neurons in a region of the brain called the substantia nigra [1]. Mitochondrial dysfunction is so central to Parkinson’s pathology that some researchers have called it a “mitochondrial disease in disguise.” Complex I of the electron transport chain, the very protein complex that depends most heavily on CoQ10, shows consistent defects in Parkinson’s patients [5][9].
A 2025 review in *Archives of Physiology and Biochemistry* examined the neuroprotective mechanisms of CoQ10 in Parkinson’s disease specifically [1]. It highlighted three distinct ways CoQ10 appears to protect dopaminergic neurons:
1. Mitochondrial protection, by restoring electron transport chain function and improving ATP production in vulnerable neurons 2. Ferroptosis inhibition, by preventing a specific form of cell death driven by iron-dependent lipid peroxidation, which is increasingly recognised as relevant in Parkinson’s 3. Antioxidant recycling, by regenerating other antioxidant defences that are depleted during oxidative stress
In animal models, CoQ10 supplementation has consistently shown meaningful neuroprotective effects, preserving dopaminergic neurons, reducing oxidative damage markers, and slowing disease progression [9]. The 2021 review in *Physiological Research* confirmed that CoQ10 “seems reasonable to recommend as adjunct therapy in some cases,” while also noting frankly that supplementation has proven “more efficient in animal models than in human patients” [9].
Why the gap? More on that shortly.
Evidence grade: Promising in animal models. Early stage in humans. The mechanisms are well-established; the clinical translation is the unresolved challenge.
Alzheimer’s disease research has long focused on amyloid plaques and tau tangles, the protein deposits that accumulate in the brains of people with the condition. But a growing body of work suggests that mitochondrial dysfunction may not just be a consequence of these changes, but an early driver of them [7].
A 2024 review in *Antioxidants* laid out the evidence carefully. It described how amyloid-beta, the protein fragment central to Alzheimer’s pathology, appears to damage the mitochondrial electron transport chain directly, reducing the activity of the complexes that depend on CoQ10 [7]. This creates a downward spiral: reduced CoQ10 activity → less ATP production → more oxidative stress → more amyloid-beta toxicity → further mitochondrial damage.
Crucially, the review argued that CoQ10’s role in maintaining “oxidative phosphorylation efficiency” makes it a plausible candidate for preventing or slowing this cascade, particularly if intervened early, before extensive neuronal damage has occurred [7]. An earlier 2015 paper in *Oxidative Medicine* similarly positioned CoQ10 as part of a “mitochondrial medicine” approach, noting that antioxidant supplementation including CoQ10 showed “mild to moderate improvement in dementia” in some studies, particularly in early-stage disease [14].
A broader 2020 review in *Cells* examining dietary substances for neurodegenerative disease prevention also included CoQ10 among the most promising endogenous compounds, while emphasising that brain bioavailability, getting CoQ10 from the bloodstream into brain tissue, remains a key research question [13].
Evidence grade: Early stage to Promising. There is a scientifically coherent mechanism and some encouraging signals. Definitive clinical trial evidence in humans remains limited.
CoQ10 deficiency isn’t just associated with Parkinson’s and Alzheimer’s. The breadth of conditions linked to mitochondrial dysfunction, and by extension, potential CoQ10 relevance, is striking.
A 2023 review in the *Biochemical Pharmacology* family of journals catalogued CoQ10’s potential relevance across Huntington’s disease, ALS (amyotrophic lateral sclerosis), Friedreich’s ataxia, multiple sclerosis, migraine, and even depression [6]. In Huntington’s disease and Friedreich’s ataxia, genetic mutations directly impair mitochondrial function, and CoQ10 supplementation has been studied as a supportive measure. In ALS, where motor neuron degeneration is associated with mitochondrial abnormalities, early trials showed some signals but no definitive benefit [9].
A 2022 paper in the *International Journal of Molecular Sciences* took a broader nutritional view, making the case that a combination approach, CoQ10 alongside B vitamins, NADH, L-carnitine, vitamin D, and alpha-lipoic acid, may be more effective than CoQ10 alone, because these nutrients all support different aspects of mitochondrial function [10]. The logic here is sound: mitochondria are complex systems, and supporting them from multiple angles simultaneously may be more effective than a single intervention.
The 2021 *Physiological Research* review also noted CoQ10’s relevance to migraine, a condition with strong evidence for mitochondrial involvement, where the clinical evidence is arguably stronger than in the major neurodegenerative diseases [9].
A 2005 paper in *Alternative Medicine Review*, one of the earlier comprehensive frameworks for this approach, outlined how multiple neurodegenerative conditions share the common thread of mitochondrial energy insufficiency, and positioned CoQ10 as a cornerstone of an integrative supplementation strategy [15].
Evidence grade: Promising for migraine. Early stage for most other neurological conditions. The common mitochondrial thread is compelling; individual condition evidence varies considerably.
One area of CoQ10 research that receives less public attention but deserves mention is traumatic brain injury (TBI). A 2025 overview in the *International Journal of Molecular Sciences* made the case that the chain of events following head trauma, ischaemia (reduced blood flow), mitochondrial dysfunction, oxidative stress, and inflammation, maps closely onto exactly the processes CoQ10 is known to modulate [4].
The paper also raised a particularly interesting practical consideration: TBI patients have an elevated risk of cardiac complications, and given CoQ10’s established role in supporting cardiac function, supplementation might address both neurological and cardiovascular aspects of TBI recovery simultaneously [4].
The review also discussed an intriguing potential delivery innovation, intranasal CoQ10, which could bypass the blood-brain barrier entirely by travelling directly along the olfactory nerve pathway to the brain. This remains experimental but represents one of the more creative solutions to the bioavailability problem.
Evidence grade: Early stage. Mainly animal models and mechanistic rationale. Human clinical trials in TBI patients are needed.
This is the section that matters most for intellectual honesty, and it’s where CoQ10 research runs into a significant wall.
The blood-brain barrier problem is real and unresolved.
Here is the central paradox of CoQ10 and brain health: the animal research is consistently encouraging, but randomised controlled trials in humans with Parkinson’s, Alzheimer’s, and ALS have largely produced disappointing results [2][11]. The leading explanation? We are not confident that CoQ10, taken orally, can cross the blood-brain barrier (BBB) in meaningful quantities in humans.
The BBB is exactly what it sounds like: a highly selective barrier that protects the brain from substances in the bloodstream. CoQ10 is a large, fat-soluble molecule, not the easiest thing to transport across this barrier. Two 2025 reviews specifically dedicated to this question examined the peer-reviewed literature on BBB permeability and found the evidence “currently uncertain” [2][11]. Some studies suggest partial penetration; others suggest very little. The honest answer is: we don’t know enough yet.
This doesn’t mean oral supplementation has no neurological benefit. Some researchers argue that CoQ10 may exert indirect neuroprotective effects, protecting the cardiovascular system and thus improving cerebral blood flow, reducing systemic inflammation, or supporting mitochondria in neurons outside the strict BBB. But these are hypotheses, not established facts.
The dosing question is also unresolved. Clinical trials have used widely varying doses, from 300mg to 2,400mg per day, making it hard to draw conclusions across studies [9]. Formulation matters enormously too, CoQ10 is notoriously poorly absorbed in standard forms, and newer approaches (nanoemulsions, ubiquinol form, next-generation analogues) may perform very differently.
Next-generation CoQ10 analogues may be the real story. A 2025 study examined Q-Der (Q10-diacetate), a CoQ10 derivative designed to improve bioavailability and neuroprotection in hippocampal neurons under oxidative stress conditions [3]. Research into structural analogues like MitoQ, designed specifically to concentrate inside mitochondria, and idebenone is ongoing [9]. These modified forms may ultimately prove more effective than standard CoQ10 at reaching the brain, but the human trial data is not yet there.
Timing may be everything. Multiple reviews suggest that CoQ10 may be most effective early, before significant neuronal loss has occurred, which creates a fundamental challenge for clinical trials that typically enrol patients with established disease [7][14].
So where does this leave you, a sensible person in your forties, fifties, or sixties who wants to take practical action to support your brain health?
Here’s how a well-informed friend would reason through this with you.
First, the honest framing: CoQ10 is not a proven treatment for Alzheimer’s or Parkinson’s disease. If anyone tells you it is, they’re overstating the evidence. The clinical trials in established neurodegenerative disease have been underwhelming, and the blood-brain barrier question remains genuinely open.
But here’s the other side of that coin: The mechanistic science, the understanding of *why* CoQ10 would matter, is some of the most coherent and well-characterised in all of nutritional neuroscience. The evidence that mitochondrial dysfunction drives neurodegeneration is strong. The evidence that CoQ10 is central to mitochondrial health is strong. The evidence that CoQ10 levels decline with age is strong [6][10]. And the safety profile of CoQ10 supplementation is excellent, it is well-tolerated even at high doses, with no serious adverse effects documented in humans or animal models [9].
For someone in midlife, focused on prevention rather than treatment, the risk-benefit calculation looks quite different from someone enrolled in a clinical trial for established Parkinson’s. The risk of deficiency, given age-related decline in CoQ10 synthesis and the fact that the brain is extraordinarily mitochondria-dependent, is real. The cost of supplementation is modest. The safety is well-established. The evidence that systemic CoQ10 status matters for mitochondrial function throughout the body, including in cardiovascular health and systemic inflammation, is solid.
Practical suggestions, grounded in what the research actually supports:
– Consider the form. Standard CoQ10 (ubiquinone) is poorly absorbed. Ubiquinol, the reduced, active form, has better bioavailability. Nano-formulations or emulsified preparations absorb better still. If you’re supplementing, form matters [9][13]. – Think about a mitochondrial stack. The 2022 review made a compelling case that CoQ10 works within a system, B vitamins, NADH, L-carnitine, vitamin D, and alpha-lipoic acid all support different aspects of the same mitochondrial machinery [10]. A combination approach is likely more effective than CoQ10 in isolation. – Don’t wait for symptoms. If the research tells us anything, it’s that mitochondrial decline begins well before neurological symptoms appear, and intervention may be most valuable early [7][14]. – Think of it as part of a broader strategy. Diet, exercise, sleep, and stress management all profoundly affect mitochondrial health. CoQ10 supplementation makes most sense as one layer of a broader commitment to brain health, not a standalone solution. – Watch this space. The next-generation CoQ10 analogues and novel delivery systems (including intranasal approaches) represent genuinely exciting directions. The science here is moving fast [3][4].
CoQ10 won’t fix a broken brain. But for someone serious about supporting their brain’s energy systems for the long haul, starting now, before the decline becomes clinically apparent, the case for thoughtful supplementation, at appropriate doses and in bioavailable forms, is reasonable and honest.
That’s not overselling. That’s applying common sense to what the research actually shows.
[1] Mechanistic insights into ubiquinone Q10 in Parkinson’s disease: mitochondrial protection, ferroptosis inhibition, and antioxidant recycling (2025). DOI: 10.1080/13813455.2025.2541698 | https://pubmed.ncbi.nlm.nih.gov/40762836/
[2] Coenzyme Q10 and the Blood-Brain Barrier: An Overview (2025). https://pubmed.ncbi.nlm.nih.gov/40283578/
[3] Q-Der: a next-generation CoQ10 analogue supercharging neuroprotection by combating oxidative stress and enhancing mitochondrial function (2025). https://pubmed.ncbi.nlm.nih.gov/40070687/
[4] Traumatic Brain Injury and Coenzyme Q10: An Overview (2025). DOI: 10.3390/ijms26115126 | https://pubmed.ncbi.nlm.nih.gov/40507939/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12154391/
[5] Mitochondrial Dysfunction in the Inflammatory Process of Neurodegenerative Diseases (2026). DOI: 10.3390/biomedicines14030682 | https://pubmed.ncbi.nlm.nih.gov/41898328/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13024686/
[6] Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases (2023). https://pubmed.ncbi.nlm.nih.gov/37946741/
[7] CoQ10 and Mitochondrial Dysfunction in Alzheimer’s Disease (2024). DOI: 10.3390/antiox13020191 | https://pubmed.ncbi.nlm.nih.gov/38397789/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885987/
[8] Mechanistic insights into ubiquinone Q10 in Parkinson’s disease: mitochondrial protection, ferroptosis inhibition, and antioxidant recycling (2025). DOI: 10.1080/13813455.2025.2541698 | https://pubmed.ncbi.nlm.nih.gov/40762836/
[9] Coenzyme Q10 effects in neurological diseases (2021). DOI: 10.33549/physiolres.934712 | https://pubmed.ncbi.nlm.nih.gov/35199552/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054193/
[10] Mitochondrial Dysfunction and Neurodegenerative Disorders: Role of Nutritional Supplementation (2022). DOI: 10.3390/ijms232012603 | https://pubmed.ncbi.nlm.nih.gov/36293457/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604531/
[11] Coenzyme Q10 and the Blood-Brain Barrier: An Overview (2025). https://pubmed.ncbi.nlm.nih.gov/40283578/
[12] Neuroprotective effects of coenzyme Q10 on neurological diseases: a review article (2023). https://pubmed.ncbi.nlm.nih.gov/37424991/
[13] An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases (2020). DOI: 10.3390/cells9030576 | https://pubmed.ncbi.nlm.nih.gov/32121302/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140513/
[14] Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease (2015). https://pubmed.ncbi.nlm.nih.gov/25986626/
[15] Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management (2005). https://pubmed.ncbi.nlm.nih.gov/16366737/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
Quick Read Your gut bacteria and brain communicate through a direct pathway. When you eat prebiotic fibre, your gut bacteria
The nutrients that matter, the forms that work, and the claims to ignore.
